16 September 2026 editorial review · Trial
LY3938577 Phase 2 in type 2 diabetes (not a T1D result): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Removed globalmost advanced / best available claims. ExplicitT2D population and noninferiority question do not establish mechanism or benefit in T1D.
Registry: NCT07215312; ACTIVE_NOT_RECRUITING; updated 2026-07-13; enrollment 100 (ESTIMATED); results not posted.
Endpoint comparison: Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) (Baseline through Week 20).
Sources for this record: A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.